{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T18:19:21Z","timestamp":1793643561632,"version":"4.5.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,3,15]],"date-time":"2026-03-15T00:00:00Z","timestamp":1773532800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,15]],"date-time":"2026-03-15T00:00:00Z","timestamp":1773532800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"name":"European Union's seventh framework programme Technological Articles Development, and Demonstration French society paediatric oncology Ligue contre le cancer"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2026,5,20]]},"DOI":"10.1038\/s41416-026-03367-4","type":"journal-article","created":{"date-parts":[[2026,3,15]],"date-time":"2026-03-15T03:35:39Z","timestamp":1773545739000},"page":"1393-1402","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Addition of zoledronic acid to consolidation chemotherapy in Ewing sarcoma\u2014EURO EWING 2012 (EE2012): an international, open-label, randomised controlled phase III trial"],"prefix":"10.1038","volume":"134","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-2805-8079","authenticated-orcid":false,"given":"Brennan","family":"Bernadette","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Kirton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Perrine","family":"Marec-B\u00e9rard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1827-8903","authenticated-orcid":false,"given":"Nathalie","family":"Gaspar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerie","family":"Laurence","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Mart\u00edn-Broto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Gelderblom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cormac","family":"Owens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Anderton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra J.","family":"Strauss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Wingrove","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica","family":"Moroz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy","family":"Whelan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa L.","family":"Hjalgrim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith","family":"Wheatley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8665-300X","authenticated-orcid":false,"given":"Piers","family":"Gaunt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,15]]},"reference":[{"key":"3367_CR1","unstructured":"de Alava E, Ewing sarcoma, in World Health Organization Classification of Tumours; Pathology and Genetics of Tumours of Soft Tissue and Bone IARC. 2013:305\u20139."},{"key":"3367_CR2","doi-asserted-by":"publisher","first-page":"4148","DOI":"10.1200\/JCO.2011.41.5703","volume":"30","author":"RB Womer","year":"2012","unstructured":"Womer RB, West DC, Krailo MD, Dickman PS, Pawel BR, Grier HE, et al. Randomized controlled trial of interval-compressed chemotherapy for the treatment of localized Ewing sarcoma: a report from the Children\u2019s Oncology Group. J Clin Oncol. 2012;30:4148\u201354.","journal-title":"J Clin Oncol"},{"key":"3367_CR3","doi-asserted-by":"publisher","first-page":"2440","DOI":"10.1200\/JCO.2013.54.4833","volume":"32","author":"MC Le Deley","year":"2014","unstructured":"Le Deley MC, Paulussen M, Lewis I, Brennan B, Ranft A, Whelan J, et al. Cyclophosphamide compared with ifosfamide in consolidation treatment of standard-risk Ewing sarcoma: results of the randomized noninferiority Euro-EWING99-R1 trial. J Clin Oncol. 2014;32:2440\u20138.","journal-title":"J Clin Oncol"},{"key":"3367_CR4","doi-asserted-by":"publisher","first-page":"3284","DOI":"10.1200\/JCO.2009.22.9864","volume":"28","author":"R Ladenstein","year":"2010","unstructured":"Ladenstein R, Potschager U, Le Deley MC, Whelan J, Paulussen M, Oberlin O, et al. Primary disseminated multifocal Ewing sarcoma: results of the Euro-EWING 99 trial. J Clin Oncol. 2010;28:3284\u201391.","journal-title":"J Clin Oncol"},{"key":"3367_CR5","doi-asserted-by":"publisher","first-page":"2970","DOI":"10.1093\/annonc\/mds117","volume":"23","author":"R Luksch","year":"2012","unstructured":"Luksch R, Tienghi A, Sundby Hall K, Fagioli F, Picci P, Barbieri E, et al. Primary metastatic Ewing\u2019s family tumors: results of the Italian Sarcoma Group and Scandinavian Sarcoma Group ISG\/SSG IV Study including myeloablative chemotherapy and total-lung irradiation. Ann Oncol. 2012;23:2970\u20136.","journal-title":"Ann Oncol"},{"key":"3367_CR6","doi-asserted-by":"publisher","first-page":"11001","DOI":"10.1200\/JCO.2016.34.15_suppl.11001","volume":"34","author":"U Dirksen","year":"2016","unstructured":"Dirksen U, Brennan B, Le Deley MC, Cozic N, van den Berg H, Bhadri V, et al. Efficacy of busulfan-melphalan high dose chemotherapy consolidation (BuMel) compared to conventional chemotherapy combined with lung irradiation in Ewing sarcoma (ES) with primary lung metastases: results of EURO-EWING 99-R2pulm randomized trial (EE99R2pul). J Clin Oncol. 2016;34:11001\u201311001.","journal-title":"J Clin Oncol"},{"key":"3367_CR7","doi-asserted-by":"publisher","first-page":"3044","DOI":"10.1200\/JCO.1998.16.9.3044","volume":"16","author":"M Paulussen","year":"1998","unstructured":"Paulussen M, Ahrens S, Craft AW, Dunst J, Fr\u00f6hlich B, Jabar S, et al. Ewing\u2019s tumors with primary lung metastases: survival analysis of 114 (European Intergroup) Cooperative Ewing\u2019s Sarcoma Studies patients. J Clin Oncol. 1998;16:3044\u201352.","journal-title":"J Clin Oncol"},{"key":"3367_CR8","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/591698","volume":"2015","author":"SK Tanguturi","year":"2015","unstructured":"Tanguturi SK, George S, Marcus KJ, Demetri GD, Baldini EH. Whole lung irradiation in adults with metastatic Ewing sarcoma: practice patterns and implications for treatment. Sarcoma. 2015;2015:591698.","journal-title":"Sarcoma"},{"key":"3367_CR9","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1016\/j.ijrobp.2014.04.036","volume":"89","author":"DL Casey","year":"2014","unstructured":"Casey DL, Alektiar KM, Gerber NK, Wolden SL. Whole lung irradiation for adults with pulmonary metastases from Ewing sarcoma. Int J Radiat Oncol Biol Phys. 2014;89:1069\u201375.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"3367_CR10","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/s00066-008-1810-x","volume":"184","author":"T B\u00f6lling","year":"2008","unstructured":"B\u00f6lling T, Schuck A, Paulussen M, Dirksen U, Ranft A, K\u00f6nemann S, et al. Whole lung irradiation in patients with exclusively pulmonary metastases of Ewing tumors. Toxicity analysis and treatment results of the EICESS-92 trial. Strahlenther Onkol. 2008;184:193\u20137.","journal-title":"Strahlenther Onkol"},{"key":"3367_CR11","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1002\/cncr.11701","volume":"98","author":"LS Rosen","year":"2003","unstructured":"Rosen LS, Gordon D, Kaminski M, Howell A, Belch A, Mackey J, et al. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer. 2003;98:1735\u201344.","journal-title":"Cancer"},{"key":"3367_CR12","first-page":"3180","volume":"13","author":"S Berry","year":"2006","unstructured":"Berry S, Waldron T, Winquist E, Lukka H. The use of bisphosphonates in men with hormone-refractory prostate cancer: a systematic review of randomized trials. Can J Urol. 2006;13:3180\u20138.","journal-title":"Can J Urol"},{"key":"3367_CR13","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1097\/00001813-200310000-00013","volume":"14","author":"J Sonnemann","year":"2003","unstructured":"Sonnemann J, Eckervogt V, Truckenbrod B, Boos J, Winkelmann W, van Valen F. The bisphosphonate pamidronate is a potent inhibitor of Ewing\u2019s sarcoma cell growth in vitro. Anti-Cancer Drugs. 2003;14:767.","journal-title":"Anti-Cancer Drugs"},{"key":"3367_CR14","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1002\/cncr.21383","volume":"104","author":"ZC Zhou","year":"2005","unstructured":"Zhou ZC, Guan H, Duan X, Kleinerman ES. Zoledronic acid inhibits primary bone tumor growth in Ewing sarcoma. Cancer. 2005;104:1713\u201320.","journal-title":"Cancer"},{"key":"3367_CR15","doi-asserted-by":"publisher","first-page":"7610","DOI":"10.1158\/0008-5472.CAN-09-4272","volume":"70","author":"GA Odri","year":"2010","unstructured":"Odri GA, Dumoucel S, Picarda G, Battaglia S, Lamoureux F, Corradini N, et al. Zoledronic acid as a new adjuvant therapeutic strategy for Ewing\u2019s sarcoma patients. Cancer Res. 2010;70:7610\u20139.","journal-title":"Cancer Res"},{"key":"3367_CR16","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1016\/S0140-6736(22)01790-1","volume":"400","author":"B Brennan","year":"2022","unstructured":"Brennan B, Kirton L, Marec-B\u00e9rard P, Gaspar N, Laurence V, Mart\u00edn-Broto J, et al. Comparison of two chemotherapy regimens in patients with newly diagnosed Ewing sarcoma (EE2012): an open-label, randomised, phase 3 trial. Lancet. 2022;400:1513\u201321.","journal-title":"Lancet"},{"key":"3367_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-019-4026-8","volume":"21","author":"J Anderton","year":"2020","unstructured":"Anderton J, Moroz V, Marec-Berard P, Gaspar N, Laurence V, Mart\u00edn-Broto J, et al. International randomised controlled trial for the treatment of newly diagnosed EWING sarcoma family of tumours - EURO EWING 2012 Protocol. Trials. 2020;21:96.","journal-title":"Trials"},{"key":"3367_CR18","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1016\/S1470-2045(16)30096-1","volume":"8","author":"S Piperno-Neumann","year":"2016","unstructured":"Piperno-Neumann S, Le Deley MC, R\u00e9dini F, Pacquement H, Marec-Berard P, Petit P, et al. Zoledronate in combination with chemotherapy and surgery to treat osteosarcoma (OS2006): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol. 2016;8:1070\u201380.","journal-title":"Lancet Oncol"},{"key":"3367_CR19","doi-asserted-by":"publisher","first-page":"5057","DOI":"10.1158\/1078-0432.CCR-23-1966","volume":"29","author":"R Koch","year":"2023","unstructured":"Koch R, Haveman L, Ladenstein R, Brichard B, J\u00fcrgens H, Cyprova S, et al. Zoledronic acid add-on therapy for standard-risk Ewing sarcoma patients in the Ewing 2008R1 trial. Clin Cancer Res. 2023;29:5057\u201368.","journal-title":"Clin Cancer Res"},{"key":"3367_CR20","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1515\/jpem-2006-190410","volume":"19","author":"E Unal","year":"2006","unstructured":"Unal E, Abaci A, Bober E, B\u00fcy\u00fckgebiz A. Efficacy and safety of oral alendronate treatment in children and adolescents with osteoporosis. J Pediatr Endocrinol Metab. 2006;19:523\u20138.","journal-title":"J Pediatr Endocrinol Metab"},{"key":"3367_CR21","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1111\/j.1651-2227.2000.tb01214.x","volume":"89","author":"R Lala","year":"2000","unstructured":"Lala R, Matarazzo P, Bertelloni S, Buzi F, Rigon F, de Sanctis C. Pamidronate treatment of bone fibrous dysplasia in nine children with McCune-Albright syndrome. Acta Paediatr. 2000;89:188\u201393.","journal-title":"Acta Paediatr"},{"key":"3367_CR22","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.bone.2005.02.020","volume":"37","author":"D Heymann","year":"2005","unstructured":"Heymann D, Ory B, Blanchard F, Heymann MF, Coipeau P, Charrier C, et al. Enhanced tumor regression and tissue repair when zoledronic acid is combined with ifosfamide in rat osteosarcoma. Bone. 2005;37:74\u201386.","journal-title":"Bone"},{"key":"3367_CR23","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1016\/S1470-2045(14)70302-X","volume":"15","author":"R Coleman","year":"2014","unstructured":"Coleman R, Cameron D, Dodwell D, Bell R, Wilson C, Rathbone E, et al. Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01\/04) randomised open-label phase 3 trial. Lancet Oncol. 2014;15:997\u20131006.","journal-title":"Lancet Oncol"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03367-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03367-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03367-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T06:28:45Z","timestamp":1777530525000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03367-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,15]]},"references-count":23,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,5,20]]}},"alternative-id":["3367"],"URL":"https:\/\/doi.org\/10.1038\/s41416-026-03367-4","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,15]]},"assertion":[{"value":"7 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"LK declares grant funding from Cancer Research UK and Bayer unrelated to this work. JM-B reports institutional grants from PharmaMar, Lilly, Lixte Biotecnologia, Terapeutica Karyopharm, Deciphera, Bristol Myers-Squibb, Pfizer, Inhibrx, Ayala Pharmaceuticals, Philogen, Cebiotex, PTC Therapeutics, RAN Therapeutics, Boehringer Ingelheim, Synox, Abbisko, Biosplice, Immunome, BMS, SpringWorks Therapeutics; royalties\/licences from PharmaMar; consulting fees from PharmaMar, Glaxosmithkline, Bayer, Roche, Tecnofarma, Asofarma, Boehringer Ingelheim, Cogent Biosciences, Deciphera; honoraria from Pharmamar; payment for expert testimony from PharmaMar, Glaxosmithkline, Bayer, Roche, Tecnofarma, Asofarma, Boehringer Ingelheim, Cogent Biosciences, Deciphera; support for meetings from PharmaMar; and leadership role for Sarcoma Research Solutions SL. SJS declares honoraria from Boehringer Ingelheim and participation on a safety monitoring board for Ipsen; Inhibrx; Tessallate Bio; Awen Oncology and Ewing Sarcoma Institute. VM has since moved employment, but her new employer has no relationship with this work. PG declares grant funding from Cancer Research UK and Bayer unrelated to this work. We declare no other competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki and the Good Clinical Practice guidelines. Informed written consent was obtained from all patients\/parents\/legal guardians as per local practice. Before commencing the study, approval was gained from the relevant competent authority and ethical committee in each country. The trial was prospectively registered with EudraCT 2012-002107-17 and ISRCTN 54540667.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}